The EGFR inhibitor osimertinib is now available as a monotherapy for certain patients with locally advanced, unresectable non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved osimertinib (Tagrisso) to treat...
The AACR spotlights cancer advances and challenges in new report, and the FDA approves second CDK 4/6 inhibitor to reduce risk of recurrence in early-stage breast cancer.
The CD38-targeted antibody was approved for patients who are ineligible for stem cell transplant. The U.S. Food and Drug Administration (FDA) has approved isatuximab-irfc (Sarclisa) in combination with VRd (a regimen consisting of bortezomib...
Amivantamab with carboplatin and pemetrexed was approved for some advanced non-small cell lung cancers that progressed on or after EGFR inhibition. The U.S. Food and Drug Administration (FDA) has approved amivantamab-vmjw (Rybrevant) plus the...
Some patients with stage 2 or 3 breast cancer may now receive ribociclib with an aromatase inhibitor after surgery. The U.S. Food and Drug Administration (FDA) has approved ribociclib (Kisqali) in combination with an...
Pembrolizumab plus chemotherapy was approved for certain patients with untreated malignant pleural mesothelioma. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) with the chemotherapeutic pemetrexed and platinum-based chemotherapy as first-line therapy...
Mammogram findings will now include information about breast density, and youth vaping is on the decline.
The FDA approved atezolizumab and hyaluronidase-tqjs for all adult indications of intravenous atezolizumab. The U.S. Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as a subcutaneous injection to be offered...
The study, published in an AACR journal, comes after an FDA warning regarding the potential for secondary malignancies after CAR T cells are used for B-cell lymphoma or multiple myeloma. Patients who receive CAR...
Bianca Islam, MD, PhD, examines how social determinants of health impact cancer patients and what is being done to address these issues.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More